Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

18.95 -0.05 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 172,917
Open 19.04
Bid (Size) 18.75 (3)
Ask (Size) 19.50 (28)
Prev. Close 19.00
Today's Range 18.62 - 19.57
52wk Range 17.52 - 45.00
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unveiling 3 Analyst Insights On Arcturus Therapeutics
Via Benzinga
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
Via Benzinga
Exposures COVID-19

Performance

YTD
-42.73%
-42.73%
1 Month
-12.95%
-12.95%
3 Month
-20.84%
-20.84%
6 Month
-28.84%
-28.84%
1 Year
+2.93%
+2.93%

More News

Read More
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
Via Benzinga
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
Via Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Via Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
Via Benzinga
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
From Achilles Therapeutics PLC
Via GlobeNewswire
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.